The management of high-risk, locally advanced, prostate cancer radiation therapy

Authors

  • Swetha Sridharan Department of Radiation Oncology, University of Toronto and the Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON
  • Padraig Warde Department of Radiation Oncology, University of Toronto and the Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.20

Abstract

Downloads

Download data is not yet available.

Author Biographies

Swetha Sridharan, Department of Radiation Oncology, University of Toronto and the Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON

Padraig Warde, Department of Radiation Oncology, University of Toronto and the Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON

References

Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Int J Cancer 2008;127:2893-917. http://dx.doi.org/10.1002/ijc.25516

Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development.

Can J Urol 2001;8:1314-22.

D’Amico AV, D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy,

external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate

cancer. JAMA 1998;280:969-74. http://dx.doi.org/10.1001/jama.280.11.969

Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long term androgen

suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Lancet Oncol 2010;11:1066-73. http://dx.doi.org/10.1016/S1470-2045(10)70223-0

Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for

locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104-11. http://dx.doi.

org/10.1016/S0140-6736(11)61095-7

Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally

advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase 3 trail. Lancet 2009;373:301-8.

http://dx.doi.org/10.1016/S0140-6736(08)61815-2

Mottet N, Peneau M, Mazeron JJ, et al. Addition of radiotherapy to long-term androgen deprivation in

locally advanced prostate cancer: An open randomised phase 3 trial. Eur Urol 2012;62:213-9. http://

dx.doi.org/10.1016/j.eururo.2012.03.053

Brundage M, Parulekar W, Chen B, et al. The impact of Radiotherapy on Quality of Life when give in

combination with ADT for locally advanced prostate cancer : QoL results from the NCIC CTG PR3/MRCPR07

randomised trial. Radiother Oncol 2012;104:s73.

Zietman AL, Bae K, Slater J, et al. Randomized Trial Comparing Conventional-Dose With High-Dose

Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From

Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11.

http://dx.doi.org/10.1200/JCO.2009.25.8475

Kuban DA, Tucker S, Dong L, et al. Long-term results of the M.D Anderson randomized dose escalation

trial for prostate cancer. IJROBP 2008;70:67-74.

Peeters S, Heemsbergen W D, Koper P, et al. Dose reponse in radiotherapy for localized prostate cancer:

Results of the Dutch Multicenter Randomised Phase III trial comparing 68Gy of Radiotherapy with 78Gy.

J Clin Oncol 2006;24:1990-6. http://dx.doi.org/10.1200/JCO.2005.05.2530

Zelefsky MJ, Reuter VE, Zvi F, et al. Influence of Local tumour Control on Distant metastases and Cancer

related mortality after external beam radiotherapy for prostate cancer. J Urol 2008;179:1368-73. http://

dx.doi.org/10.1016/j.juro.2007.11.063

Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam

radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of

the prostate. J Clin Oncol 2005;23:1192-9. http://dx.doi.org/10.1200/JCO.2005.06.154

Downloads

Published

2012-12-05

How to Cite

Sridharan, S., & Warde, P. (2012). The management of high-risk, locally advanced, prostate cancer radiation therapy. Canadian Urological Association Journal, 6(5). https://doi.org/10.5489/cuaj.20

Issue

Vol. 6 No. 5 (2012): CUAJ October

Section

Point-Counterpoint

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.